Stocktoria
Entrada Therapeutics, Inc. TRDA
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-10-29
Entrada Therapeutics, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $25.4M | $210.8M | $129.0M | — | — | — |
| R&D expense | $142.3M | $125.3M | $99.9M | $66.6M | $35.9M | $21.1M |
| Operating income | -$157.9M | $47.0M | -$3.2M | -$97.2M | -$51.1M | -$26.7M |
| Income tax | $924,000 | $859,000 | $18.7M | $0 | $0 | $0 |
| Net income | -$143.8M | $65.6M | -$6.7M | -$94.6M | -$51.2M | -$26.5M |
| EPS (diluted) | $-3.47 | $1.68 | $-0.20 | $-3.02 | $-8.16 | $-24.00 |
| Operating cash flow | -$128.5M | -$41.6M | $139.8M | -$93.8M | -$50.9M | -$25.6M |
| Free cash flow | -$129.6M | -$44.7M | $134.2M | -$96.7M | -$55.4M | -$27.9M |
| Cash & equivalents | $90.4M | $101.2M | $67.6M | $45.2M | $291.1M | $39.0M |
| Total assets | $377.4M | $526.3M | $469.2M | $252.1M | $305.8M | $43.5M |
| Total liabilities | $71.2M | $97.6M | $226.8M | $39.5M | $7.1M | $3.4M |
| Shareholders' equity | $306.1M | $428.7M | $242.4M | $212.6M | $298.7M | -$41.5M |
Growth · year-over-year · Revenue CAGR -55.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | -87.9% | +63.4% | — | — | — | — |
| Net income growth | -319.0% | — | — | — | — | — |
| EPS growth | -306.5% | — | — | — | — | — |
| Free cash flow growth | — | -133.3% | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.